GPHRA
gene geneOn this page
Also known as GPHRUNQ192
Summary
GPHRA (golgi pH regulator A, HGNC:31984) is a protein-coding gene on chromosome 1q21.1, encoding Golgi pH regulator A (B7ZAQ6). Voltage-gated channel that enables the transfer of monoatomic anions such as iodide, chloride, bromide and fluoride which may function in counter-ion conductance and participates in Golgi acidification.
Enables voltage-gated monoatomic anion channel activity. Involved in intracellular pH reduction. Located in Golgi cisterna membrane and Golgi-associated vesicle membrane.
Source: NCBI Gene 653519 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 57 total — 1 likely-pathogenic
- MANE Select transcript:
NM_001097612
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:31984 |
| Approved symbol | GPHRA |
| Name | golgi pH regulator A |
| Location | 1q21.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | GPHR, UNQ192 |
| Ensembl gene | ENSG00000117262 |
| Ensembl biotype | protein_coding |
| OMIM | 612821 |
| Entrez | 653519 |
Gene structure
Transcript identifiers
Ensembl transcripts: 23 — 13 protein_coding, 4 nonsense_mediated_decay, 4 retained_intron, 2 protein_coding_CDS_not_defined
ENST00000313835, ENST00000460277, ENST00000462900, ENST00000465185, ENST00000466593, ENST00000478703, ENST00000492401, ENST00000493684, ENST00000524525, ENST00000527989, ENST00000528944, ENST00000532574, ENST00000534502, ENST00000907153, ENST00000907154, ENST00000907155, ENST00000907156, ENST00000907157, ENST00000907158, ENST00000907159, ENST00000907160, ENST00000918431, ENST00000960869
RefSeq mRNA: 2 — MANE Select: NM_001097612
NM_001097612, NM_001097613
CCDS: CCDS72857, CCDS72858
Canonical transcript exons
ENST00000313835 — 14 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001597907 | 145623613 | 145623714 |
| ENSE00001863261 | 145669834 | 145670650 |
| ENSE00003473687 | 145665562 | 145665651 |
| ENSE00003476736 | 145646184 | 145646272 |
| ENSE00003514696 | 145623054 | 145623160 |
| ENSE00003518078 | 145663329 | 145663424 |
| ENSE00003548922 | 145647175 | 145647267 |
| ENSE00003553143 | 145669625 | 145669690 |
| ENSE00003555340 | 145643869 | 145643978 |
| ENSE00003559230 | 145616234 | 145616293 |
| ENSE00003595763 | 145631664 | 145631744 |
| ENSE00003625983 | 145630687 | 145630807 |
| ENSE00003668603 | 145618320 | 145618423 |
| ENSE00003846947 | 145607988 | 145608175 |
Expression profiles
Bgee: expression breadth ubiquitous, 134 present calls, max score 91.42.
FANTOM5 (CAGE): breadth broad, TPM avg 0.9157 / max 13.2807, expressed in 607 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 201670 | 0.9157 | 607 |
Top tissues by expression
134 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| corpus callosum | UBERON:0002336 | 91.42 | gold quality |
| duodenum | UBERON:0002114 | 91.32 | gold quality |
| body of pancreas | UBERON:0001150 | 89.98 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 89.90 | gold quality |
| pancreas | UBERON:0001264 | 88.88 | gold quality |
| endometrium | UBERON:0001295 | 88.80 | gold quality |
| cerebellar cortex | UBERON:0002129 | 88.57 | gold quality |
| cerebellar hemisphere | UBERON:0002245 | 88.54 | gold quality |
| cerebellum | UBERON:0002037 | 88.53 | gold quality |
| adrenal tissue | UBERON:0018303 | 88.34 | gold quality |
| rectum | UBERON:0001052 | 88.32 | gold quality |
| right hemisphere of cerebellum | UBERON:0014890 | 88.28 | gold quality |
| calcaneal tendon | UBERON:0003701 | 88.19 | gold quality |
| right lobe of liver | UBERON:0001114 | 88.00 | gold quality |
| islet of Langerhans | UBERON:0000006 | 87.99 | gold quality |
| body of stomach | UBERON:0001161 | 87.67 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 87.57 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 87.55 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 87.46 | gold quality |
| left adrenal gland | UBERON:0001234 | 87.43 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 87.32 | gold quality |
| right adrenal gland | UBERON:0001233 | 87.26 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 87.24 | gold quality |
| adrenal gland | UBERON:0002369 | 87.16 | gold quality |
| stomach | UBERON:0000945 | 87.05 | gold quality |
| pituitary gland | UBERON:0000007 | 87.04 | gold quality |
| cortex of kidney | UBERON:0001225 | 87.02 | gold quality |
| kidney | UBERON:0002113 | 87.00 | gold quality |
| adenohypophysis | UBERON:0002196 | 86.95 | gold quality |
| small intestine | UBERON:0002108 | 86.87 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 4.92 |
| E-CURD-112 | no | 3.60 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
26 targeting GPHRA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-8068 | 99.98 | 73.85 | 2376 |
| HSA-MIR-4799-5P | 99.82 | 70.60 | 2663 |
| HSA-MIR-132-3P | 99.73 | 70.56 | 1424 |
| HSA-MIR-212-3P | 99.73 | 70.65 | 1424 |
| HSA-MIR-6892-3P | 99.68 | 66.40 | 1178 |
| HSA-MIR-3679-3P | 99.64 | 69.88 | 1599 |
| HSA-MIR-24-3P | 99.59 | 69.97 | 1934 |
| HSA-MIR-199A-5P | 99.51 | 69.71 | 1107 |
| HSA-MIR-199B-5P | 99.51 | 69.74 | 1098 |
| HSA-MIR-20B-3P | 99.29 | 67.05 | 784 |
| HSA-MIR-3064-5P | 99.26 | 66.13 | 1497 |
| HSA-MIR-3085-3P | 99.26 | 66.16 | 1490 |
| HSA-MIR-6504-5P | 99.26 | 65.95 | 1487 |
| HSA-MIR-593-3P | 99.22 | 67.28 | 1327 |
| HSA-MIR-6744-3P | 99.22 | 64.41 | 972 |
| HSA-MIR-8077 | 99.17 | 66.67 | 862 |
| HSA-MIR-4757-5P | 99.12 | 64.51 | 981 |
| HSA-MIR-29A-5P | 99.08 | 68.59 | 1813 |
| HSA-MIR-622 | 98.99 | 66.48 | 1050 |
| HSA-MIR-6728-3P | 98.63 | 67.63 | 1534 |
| HSA-MIR-218-1-3P | 98.63 | 67.97 | 832 |
| HSA-MIR-93-3P | 98.15 | 66.65 | 1309 |
| HSA-MIR-4469 | 97.93 | 65.81 | 1319 |
| HSA-MIR-937-5P | 97.43 | 68.39 | 667 |
| HSA-MIR-3622A-3P | 97.06 | 66.43 | 1000 |
| HSA-MIR-3622B-3P | 96.82 | 66.36 | 988 |
Cross-species orthologs
6 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | GPR89A | ENSDARG00000077983 |
| mus_musculus | Gpr89 | ENSMUSG00000028096 |
| rattus_norvegicus | Gpr89b | ENSRNOG00000000095 |
| drosophila_melanogaster | GPHR | FBGN0033995 |
| caenorhabditis_elegans | WBGENE00007528 | |
| caenorhabditis_elegans | WBGENE00013551 |
Paralogs (1): GPR89B (ENSG00000188092)
Protein
Protein identifiers
Golgi pH regulator A — B7ZAQ6 (reviewed: B7ZAQ6)
Alternative names: Protein GPR89A, Putative MAPK-activating protein PM01, Putative NF-kappa-B-activating protein 90
All UniProt accessions (5): B7ZAQ6, E9PKY3, E9PRZ5, X5D7G6, X5DNN3
UniProt curated annotations — full annotation on UniProt →
Function. Voltage-gated channel that enables the transfer of monoatomic anions such as iodide, chloride, bromide and fluoride which may function in counter-ion conductance and participates in Golgi acidification. Plays a role in lymphocyte development, probably by acting as a RABL3 effector in hematopoietic cells.
Subunit / interactions. Homotrimer. Interacts with RABL3; the interaction stabilizes GPR89A.
Subcellular location. Golgi apparatus membrane.
Tissue specificity. Ubiquitous.
Miscellaneous. Does not seem to be able to bind GTP.
Similarity. Belongs to the Golgi pH regulator (TC 1.A.38) family.
Isoforms (4)
| UniProt ID | Names | Canonical? |
|---|---|---|
| B7ZAQ6-1 | 1 | yes |
| B7ZAQ6-2 | 2 | |
| B7ZAQ6-3 | 3 | |
| B7ZAQ6-4 | 4, A |
RefSeq proteins (2): NP_001091081, NP_001091082 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR015672 | GPHR/GTG | Family |
| IPR022535 | Golgi_pH-regulator_cons_dom | Domain |
| IPR025969 | ABA_GPCR_dom | Domain |
Pfam: PF12430, PF12537
Catalyzed reactions (Rhea), 4 shown:
- chloride(in) = chloride(out) (RHEA:29823)
- iodide(out) = iodide(in) (RHEA:66324)
- bromide(in) = bromide(out) (RHEA:75383)
- fluoride(in) = fluoride(out) (RHEA:76159)
UniProt features (19 total): transmembrane region 9, splice variant 4, sequence conflict 3, glycosylation site 2, chain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-B7ZAQ6-F1 | 82.62 | 0.35 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (2): 180, 243
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 80 (showing top):
GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOCC_GOLGI_ASSOCIATED_VESICLE, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, SANSOM_APC_TARGETS_DN, GOBP_REGULATION_OF_PH, GOBP_MONOATOMIC_ION_HOMEOSTASIS, MORI_PLASMA_CELL_UP, GOBP_POSITIVE_REGULATION_OF_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_TRANSMEMBRANE_TRANSPORT, GOCC_GOLGI_STACK, chr1q21, GOCC_GOLGI_ASSOCIATED_VESICLE_MEMBRANE, GOCC_GOLGI_CISTERNA, GOBP_HOMEOSTATIC_PROCESS
GO Biological Process (7): protein transport (GO:0015031), T cell differentiation (GO:0030217), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), intracellular pH reduction (GO:0051452), monoatomic ion transport (GO:0006811), monoatomic ion transmembrane transport (GO:0034220), monoatomic anion transmembrane transport (GO:0098656)
GO Molecular Function (1): voltage-gated monoatomic anion channel activity (GO:0008308)
GO Cellular Component (6): Golgi membrane (GO:0000139), Golgi-associated vesicle membrane (GO:0030660), Golgi cisterna membrane (GO:0032580), monoatomic ion channel complex (GO:0034702), Golgi apparatus (GO:0005794), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| transport | 2 |
| bounding membrane of organelle | 2 |
| intracellular protein localization | 1 |
| establishment of protein localization | 1 |
| lymphocyte differentiation | 1 |
| T cell activation | 1 |
| canonical NF-kappaB signal transduction | 1 |
| regulation of canonical NF-kappaB signal transduction | 1 |
| positive regulation of intracellular signal transduction | 1 |
| regulation of intracellular pH | 1 |
| monoatomic ion transport | 1 |
| transmembrane transport | 1 |
| monoatomic anion transport | 1 |
| monoatomic ion transmembrane transport | 1 |
| voltage-gated monoatomic ion channel activity | 1 |
| monoatomic anion channel activity | 1 |
| Golgi apparatus | 1 |
| Golgi-associated vesicle | 1 |
| cytoplasmic vesicle membrane | 1 |
| organelle membrane | 1 |
| Golgi cisterna | 1 |
| transmembrane transporter complex | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
908 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| GPHRA | CT47A11 | Q5JQC4 | 952 |
| GPHRA | CT47B1 | P0C2W7 | 766 |
| GPHRA | ACP6 | Q9NPH0 | 636 |
| GPHRA | FSHR | P23945 | 602 |
| GPHRA | TSHR | P16473 | 599 |
| GPHRA | PRKAB2 | O43741 | 595 |
| GPHRA | FMO5 | P49326 | 576 |
| GPHRA | POLR3GL | Q9BT43 | 539 |
| GPHRA | CHD1L | Q86WJ1 | 530 |
| GPHRA | BOLA2 | Q9H3K6 | 528 |
| GPHRA | GPHN | Q9NQX3 | 515 |
| GPHRA | LHCGR | P22888 | 512 |
| GPHRA | GPR152 | Q8TDT2 | 508 |
| GPHRA | NBPF11 | Q86T75 | 507 |
| GPHRA | GTPBP8 | Q8N3Z3 | 488 |
IntAct
111 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| NIPAL1 | ESYT2 | psi-mi:“MI:0914”(association) | 0.640 |
| SLC7A1 | TMEM223 | psi-mi:“MI:0914”(association) | 0.530 |
| IPPK | TMEM223 | psi-mi:“MI:0914”(association) | 0.530 |
| SLC39A5 | TMEM223 | psi-mi:“MI:0914”(association) | 0.530 |
| CXCR4 | TMEM120B | psi-mi:“MI:0914”(association) | 0.530 |
| GPR21 | TMEM120B | psi-mi:“MI:0914”(association) | 0.530 |
| YIPF3 | TMEM120B | psi-mi:“MI:0914”(association) | 0.530 |
| SLC39A4 | TMEM120B | psi-mi:“MI:0914”(association) | 0.530 |
| C3AR1 | TMEM120B | psi-mi:“MI:0914”(association) | 0.530 |
| LPAR1 | TMEM120B | psi-mi:“MI:0914”(association) | 0.530 |
| HTR2C | KLRG2 | psi-mi:“MI:0914”(association) | 0.530 |
| TSPAN17 | UPK3BL1 | psi-mi:“MI:0914”(association) | 0.530 |
| SLC1A5 | GPR89A | psi-mi:“MI:0914”(association) | 0.530 |
| SLC22A9 | GPR89A | psi-mi:“MI:0914”(association) | 0.530 |
| UNC93B1 | GPR89A | psi-mi:“MI:0914”(association) | 0.530 |
| P2RY6 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| SLC15A3 | psi-mi:“MI:0914”(association) | 0.350 | |
| UNC93B1 | psi-mi:“MI:0914”(association) | 0.350 | |
| P2RY6 | psi-mi:“MI:0914”(association) | 0.350 | |
| rep | GPR89A | psi-mi:“MI:0914”(association) | 0.350 |
| TMEM223 | psi-mi:“MI:0914”(association) | 0.350 | |
| M | DENND11 | psi-mi:“MI:0914”(association) | 0.350 |
| ATP2B2 | ESYT2 | psi-mi:“MI:0914”(association) | 0.350 |
| TTYH1 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| TSPAN15 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| BSCL2 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| ADGRE5 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
| CRELD1 | TMEM223 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (246): GPR89A (Affinity Capture-MS), GPR89A (Affinity Capture-MS), GPR89B (Affinity Capture-MS), GPR89B (Affinity Capture-MS), GPR89A (Affinity Capture-MS), GPR89A (Affinity Capture-MS), GPR89B (Affinity Capture-MS), GPR89A (Affinity Capture-MS), GPR89B (Affinity Capture-MS), GPR89A (Affinity Capture-MS), GPR89B (Affinity Capture-MS), GPR89B (Affinity Capture-MS), GPR89A (Affinity Capture-MS), GPR89B (Affinity Capture-MS), GPR89B (Affinity Capture-MS)
ESM2 similar proteins: B2ZXD5, B5X1G3, B7ZAQ6, B9RK42, O95214, P0CG08, Q0VGV9, Q32PD8, Q3B8G4, Q3SYY9, Q3ZBX1, Q4R5E3, Q5BIM9, Q5E9M1, Q5F3F5, Q5F433, Q5F448, Q5PQQ4, Q5PR61, Q5RDE9, Q5U4X7, Q5ZI05, Q658I5, Q68DH5, Q6AZ61, Q6CLZ9, Q6DDW6, Q6DFS0, Q6IQC7, Q6P4P2, Q6PDU4, Q7SYR6, Q7ZUA6, Q7ZX75, Q7ZYA0, Q8BH79, Q8BS95, Q8C561, Q8GWT5, Q8K0B2
Diamond homologs: A2XX57, B2ZXD5, B5X1G3, B7ZAQ6, P0CG08, Q0WQG8, Q54QM5, Q5BIM9, Q5F448, Q6DDW6, Q7X7S8, Q8BS95, Q9XIP7
SIGNOR signaling
0 interactions.
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 113 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Amino acid transport across the plasma membrane | 7 | 30.1× | 2e-07 |
| SLC-mediated transport of neurotransmitters | 5 | 29.1× | 2e-05 |
| R-HSA-425366 | 8 | 20.7× | 2e-07 |
| R-HSA-425393 | 8 | 14.8× | 2e-06 |
| SLC-mediated transmembrane transport | 14 | 11.8× | 1e-09 |
| G alpha (q) signalling events | 10 | 8.2× | 1e-05 |
| Cardiac conduction | 5 | 7.8× | 5e-03 |
| Transport of small molecules | 18 | 6.5× | 1e-08 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| complement receptor mediated signaling pathway | 5 | 56.7× | 2e-06 |
| amino acid transport | 10 | 31.5× | 4e-10 |
| adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 5 | 17.0× | 5e-04 |
| sodium ion transmembrane transport | 8 | 16.4× | 3e-06 |
| transport across blood-brain barrier | 9 | 16.3× | 7e-07 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 12 | 16.0× | 4e-09 |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 6 | 13.3× | 4e-04 |
| positive regulation of cytosolic calcium ion concentration | 9 | 10.6× | 2e-05 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
57 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 1 |
| Uncertain significance | 42 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 1331349 | NC_000001.10:g.145382933_145831892del | Likely pathogenic |
SpliceAI
2637 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 1:145616230:T:A | acceptor_loss | 1.0000 |
| 1:145616231:C:CC | acceptor_gain | 1.0000 |
| 1:145616231:C:CG | acceptor_loss | 1.0000 |
| 1:145616232:TCTG:T | acceptor_loss | 1.0000 |
| 1:145616233:ATCT:A | acceptor_loss | 1.0000 |
| 1:145616235:GTAT:G | acceptor_gain | 1.0000 |
| 1:145616292:CC:C | donor_loss | 1.0000 |
| 1:145616293:A:AG | donor_loss | 1.0000 |
| 1:145616294:CAC:C | donor_loss | 1.0000 |
| 1:145616295:TCAC:T | donor_loss | 1.0000 |
| 1:145616296:CTCAC:C | donor_loss | 1.0000 |
| 1:145616297:TCTCA:T | donor_loss | 1.0000 |
| 1:145643969:T:TA | donor_gain | 1.0000 |
| 1:145643974:T:A | donor_gain | 1.0000 |
| 1:145663325:T:A | acceptor_loss | 1.0000 |
| 1:145663326:C:CC | acceptor_gain | 1.0000 |
| 1:145663329:AGCC:A | acceptor_loss | 1.0000 |
| 1:145663330:TAGCC:T | acceptor_loss | 1.0000 |
| 1:145663423:C:CC | donor_gain | 1.0000 |
| 1:145663423:CAT:C | donor_gain | 1.0000 |
| 1:145663424:A:AC | donor_gain | 1.0000 |
| 1:145663424:AC:A | donor_loss | 1.0000 |
| 1:145663425:TACAT:T | donor_loss | 1.0000 |
| 1:145663426:TTA:T | donor_loss | 1.0000 |
| 1:145663427:CTTA:C | donor_loss | 1.0000 |
| 1:145663428:ACTT:A | donor_loss | 1.0000 |
| 1:145665551:A:T | acceptor_gain | 1.0000 |
| 1:145665552:C:CT | acceptor_gain | 1.0000 |
| 1:145665552:C:T | acceptor_gain | 1.0000 |
| 1:145665555:C:CT | acceptor_gain | 1.0000 |
AlphaMissense
3026 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS10910846 (1:145659481 G>A,C,T), RS111338698 (1:145659066 C>A,T), RS111383109 (1:145619259 A>C), RS111488177 (1:145641195 A>C), RS111533600 (1:145630557 A>T), RS111534447 (1:145634351 G>A), RS111649805 (1:145640511 A>G), RS111653456 (1:145652195 T>G), RS111698165 (1:145647104 G>A), RS111776936 (1:145659392 G>A), RS111781764 (1:145616956 G>C), RS111884698 (1:145620881 T>G), RS112052396 (1:145607628 G>C), RS112053125 (1:145666774 G>A,T), RS112067935 (1:145653884 T>A)
Disease associations
OMIM: gene MIM:612821 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
20 total (human), top 20 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| sodium arsenite | increases abundance, increases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| bisphenol A | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| deguelin | increases expression | 1 |
| abrine | increases expression | 1 |
| pyrachlostrobin | increases expression | 1 |
| jinfukang | increases expression | 1 |
| Arsenic | increases abundance, increases expression | 1 |
| Vehicle Emissions | increases abundance, increases expression | 1 |
| Benzo(a)pyrene | increases methylation | 1 |
| Cannabidiol | affects cotreatment, decreases expression | 1 |
| Cuprizone | affects cotreatment, decreases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Rotenone | increases expression | 1 |
| Valproic Acid | decreases methylation | 1 |
| Aflatoxin B1 | decreases methylation | 1 |
| Cadmium Chloride | decreases expression | 1 |
| Acrylamide | increases expression | 1 |
| Particulate Matter | increases abundance, increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.